• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

    39.83 +1.61 (+4.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 472,797
    Open 38.40
    Bid (Size) 39.50 (1)
    Ask (Size) 40.25 (1)
    Prev. Close 38.22
    Today's Range 37.48 - 40.08
    52wk Range 26.20 - 63.50
    Shares Outstanding 56,367,802
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
    From Apogee Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -15.5%
    -15.5%
    1 Month
    +5.2%
    +5.2%
    3 Month
    -8.3%
    -8.3%
    6 Month
    +6.6%
    +6.6%
    1 Year
    -32.2%
    -32.2%

    More News

    Read More
    Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    Gold Falls 1%; ProKidney Shares Spike Higher
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Dow Dips 1%; Mustang Bio Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Let's uncover which stocks are experiencing notable gaps during today's session.
    Via Chartmill
    Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
    Via Investor's Business Daily
    What's going on in today's pre-market session
    Via Chartmill
    Top 2 Health Care Stocks That May Plunge This Month
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial
    Via Benzinga
    Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
    From Apogee Therapeutics
    Via GlobeNewswire
    Why Is Apogee Therapeutics Stock Trading Higher On Monday?
    Via Benzinga
    Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
    From Apogee Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
    Via Benzinga
    Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
    From Apogee Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
    Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
    The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
    What is the current price of Apogee Therapeutics, Inc. - Common Stock?
    The current price of Apogee Therapeutics, Inc. - Common Stock is 39.83
    When was Apogee Therapeutics, Inc. - Common Stock last traded?
    The last trade of Apogee Therapeutics, Inc. - Common Stock was at 09/29/25 04:00 PM ET
    What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
    The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 2.25B
    How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
    Apogee Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.